Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
Zinforo showed high clinical cure rate and evidence of rapid response in CAP and cSSTI2,3
Explore three Phase III trials here.
Zinforo targets key pathogens in CAP and cSSTI paediatric patients from birth including Streptococcus pneumoniae (in CAP) and Staphylococcus aureus (including methicillin-resistant strains in cSSTI and methcillin-susceptible strains only in CAP).*1,8-16
*There is no experience with Zinforo in the treatment of CAP in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, severe underlying lung disease (eg cystic fibrosis), those with PORT Risk Class V, and/or CAP requiring ventilation at presentation, CAP due to methicillin-resistant S. aureus or patients requiring intensive care. Caution is advised when treating such patients.1 There is no experience with ceftaroline in the treatment of cSSTI in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, necrotizing fasciitis, perirectal abscess and patients with third degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.1
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
Zinforo 600 mg powder for concentrate for solution for infusion
Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials
** This is an optional area where footnotes can live.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020